Please assess the completion status of the following clinical trial:

Trial Title: Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any pediatric patient with an underlying diagnosis of a malignancy (excluding hematological malignancies like leukemias and lymphomas)~* ≥5% weight loss from diagnosis of primary malignancy (must be currently on chemotherapy and/or radiation therapy or scheduled to receive cancer therapy OR ≥5% weight loss following bone marrow transplant (autologous or allogeneic blood/bone marrow) and not actively receiving corticosteroid therapy~* Negative pregnancy test done =\< 7 days prior to registration for women of childbearing potential only~Exclusion Criteria:~* Receiving tube feedings or parenteral nutrition~* Evidence of ascites~* Current (within the past 28 days) or planned treatment with adrenal steroids (short-term use of dexamethasone around days of intravenous chemotherapy is allowed for protection against emesis), androgens, progestational agents, or appetite stimulants (e.g., dronabinol)~* Known mechanical obstruction of the alimentary tract, malabsorption, or intractable vomiting (\> 5 episodes/week)~* History of unresectable brain tumor or cancer metastatic to the brain~* History of thromboembolic disease~* Insulin-requiring diabetes~* Congestive heart failure and/or uncontrolled hypertension~* Anticoagulation~* Previous history of thrombosis (personal and immediate family)~* Concurrent corticosteroid therapy (except as an antiemetic)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.
- Arm B (Type: ACTIVE_COMPARATOR): Patients have clinical observation for weight loss and gain for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).